May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Inhibition of Retinal Vascular Leakage in a Transgenic Vegf Mouse Model Following Intravitreal Bevacizumab
Author Affiliations & Notes
  • T. Isaacs
    Lions Eye Institute, Perth, Perth, Australia
  • C.-M. Lai
    Lions Eye Institute, Perth, Perth, Australia
  • M. Brankov
    Lions Eye Institute, Perth, Perth, Australia
  • P. E. Rakoczy
    Lions Eye Institute, Perth, Perth, Australia
  • Footnotes
    Commercial Relationships T. Isaacs, None; C. Lai, None; M. Brankov, None; P.E. Rakoczy, None.
  • Footnotes
    Support Juvenile Diabetes Research Foundation International (USA), National Health and Medical Research Council (Australia).
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3405. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Isaacs, C.-M. Lai, M. Brankov, P. E. Rakoczy; Inhibition of Retinal Vascular Leakage in a Transgenic Vegf Mouse Model Following Intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3405. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: The kimba mouse (trVEGF029) is a transgenic model for retinal neovascularization. It is characterized by moderate VEGF expression in photoreceptors, relatively limited neovascular changes and minimal retinal damage. The purpose of this study was to assess the effect of a single intravitreal injection of bevacizumab on the development of typical retinal vascular changes observed in this phenotype.

Methods:: Fourteen trVEGF029 mice received a single intravitreal injection of bevacizumab 1microlitre (0.025mg) to one eye. Fellow eyes were used as controls. Colour fundus photography and fluorescein angiography were performed prior to injection, and at 2,4,6 and 8 weeks post-injection.

Results:: At 2 weeks post-injection there was a decrease in fluorescein leakage in 9 eyes (64%), compared to controls. Two months following intravitreal bevacizumab no difference in leakage was observed between treated and control eyes.

Conclusions:: Intravitreal bevacizumab administration in this transgenic mouse model resulted in an initial decrease in fluorescein leakage compared to controls, but this effect was not sustained. The mechanism of action of bevacizumab in this model remains to be elucidated.

Keywords: transgenics/knock-outs • retinal neovascularization • growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×